USRM Hires Senior VP of US & International Sales
Former Abbott Pharmaceuticals, Stem Cell Centers Exec Joins Team
_________________________________________
SUNRISE, FL – September 11, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced Phil Posa has joined its executive management team as Senior Vice President of U.S. & International Sales.
Posa, who brings more than 30 years of experience in the pharmaceutical, medical device and regenerative spaces, most recently served as an Executive and CEO at Stem Cell Centers of Idaho, where he assisted in the launch and management of new and existing clinics — at a rapid growth rate of approximately one clinic per month.
As part of the management process, Posa maintained quality control and efficiency company wide, starting with the successful negotiation of contracts with manufacturers and suppliers to provide the best possible product at the lowest possible cost. He was also responsible for successfully designing and initiating a shift in training curriculum by emphasizing a focus on marketing, product and protocols for treatment and conditions, which resulted in the incorporation of a seamless program for patient flow thereby allowing the company to track from lead generation to patient satisfaction following treatment.
By focusing on conversion rates, service and best possible outcomes, Posa’s successful approach in design, implementation and execution helped bring sales to an all-time monthly high, resulting in a new benchmark for the company’s profitability. It also launched regenerative medicine into traditional insurance reimbursement medical practices, thereby converting them into ‘white glove’ concierge care cash practices.
“We are ecstatic to have Phil join our team, especially when we are at a pivotal point in expansion and diversification,” said Mike Tomas, Chief Executive Officer of U.S. Stem Cell, Inc. “The ability to assist in growing our markets both domestically and internationally is one of many skill sets Phil brings to the team. Combined with his expertise in the launch and clinical expansion in the stem cell arena, he is the perfect fit for us at this time.”
Prior to his tenure at SCC, Posa also served as Senior Vice President U.S. & International Sales for Whale Imaging, Boston, and Skyline Medical, of Minnesota, respectively. He received his MBA from Rivier College in New Hampshire, and a bachelor’s degree in Biology from Stony Brook University in Stony Brook, NY. He also was certified as a Public Health Advisor by the State of New York, and as an epidemiologist by the Centers for Disease Control (CDC).
“I am very excited about the potential of U.S. Stem Cell in the U.S. and International markets, and am looking forward to building upon the world-class reputation the Company has built over the past twenty years,” said Posa. “It is a great opportunity at just the right time in the marketplace. I am looking forward to hitting the ground running to help bring USRM to its next level of success.”
Posa also received 15 All Star awards during his tenure at Abbott Pharmaceuticals as a sales leader and manager.
USRM has been instrumental in providing more than ten thousand stem cell procedures in the past 19 years for a variety of indications, including orthopedic, autoimmune, degenerative and neurological diseases. USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 288 clinics. For two consecutive years, USRM has continued to sustain substantial revenue growth, which may be attributable to an increased awareness of stem cell therapy, as Americans seek alternatives to pain management and opioids.
U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead therapy Adipocell™, as well as veterinary stem cell training, stem cell banking, and the creation and the management of stem cell clinics. To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.